Cargando…

Primary lung cancer in women after previous breast cancer

BACKGROUND: Breast cancer is the most common malignancy among women in the USA. Improved survival has resulted in increasing incidence of second primary malignancies, of which lung cancer is the most common. The United States Preventive Services Task Force (USPSTF) guidelines for lung-cancer screeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Nobel, Tamar B, Carr, Rebecca A, Caso, Raul, Livschitz, Jennifer, Nussenzweig, Samuel, Hsu, Meier, Tan, Kay See, Sihag, Smita, Adusumilli, Prasad S, Bott, Matthew J, Downey, Robert J, Huang, James, Isbell, James M, Park, Bernard J, Rocco, Gaetano, Rusch, Valerie W, Jones, David R, Molena, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765335/
https://www.ncbi.nlm.nih.gov/pubmed/35040941
http://dx.doi.org/10.1093/bjsopen/zrab115
_version_ 1784634315461623808
author Nobel, Tamar B
Carr, Rebecca A
Caso, Raul
Livschitz, Jennifer
Nussenzweig, Samuel
Hsu, Meier
Tan, Kay See
Sihag, Smita
Adusumilli, Prasad S
Bott, Matthew J
Downey, Robert J
Huang, James
Isbell, James M
Park, Bernard J
Rocco, Gaetano
Rusch, Valerie W
Jones, David R
Molena, Daniela
author_facet Nobel, Tamar B
Carr, Rebecca A
Caso, Raul
Livschitz, Jennifer
Nussenzweig, Samuel
Hsu, Meier
Tan, Kay See
Sihag, Smita
Adusumilli, Prasad S
Bott, Matthew J
Downey, Robert J
Huang, James
Isbell, James M
Park, Bernard J
Rocco, Gaetano
Rusch, Valerie W
Jones, David R
Molena, Daniela
author_sort Nobel, Tamar B
collection PubMed
description BACKGROUND: Breast cancer is the most common malignancy among women in the USA. Improved survival has resulted in increasing incidence of second primary malignancies, of which lung cancer is the most common. The United States Preventive Services Task Force (USPSTF) guidelines for lung-cancer screening do not include previous malignancy as a high-risk feature requiring evaluation. The aim of this study was to compare women undergoing resection for lung cancer with and without a history of breast cancer and to assess whether there were differences in stage at diagnosis, survival and eligibility for lung-cancer screening between the two groups. METHODS: Women who underwent lung-cancer resection between 2000 and 2017 were identified. Demographic, clinicopathological, treatment and outcomes data were compared between patients with a history of breast cancer (BC-Lung) and patients without a history of breast cancer (P-Lung) before lung cancer. RESULTS: Of 2192 patients included, 331 (15.1 per cent) were in the BC-Lung group. The most common method of lung-cancer diagnosis in the BC-Lung group was breast-cancer surveillance or work-up imaging. Patients in the BC-Lung group had an earlier stage of lung cancer at the time of diagnosis. Five-year overall survival was not statistically significantly different between groups (73.3 per cent for both). Overall, 58.4 per cent of patients (1281 patients) had a history of smoking, and 33.3 per cent (731 patients) met the current criteria for lung-cancer screening. CONCLUSION: Differences in stage at diagnosis of lung cancer and treatment selection were observed between patients with and without a history of breast cancer. Overall, there were no statistically significant differences in genomic or oncogenic pathway alterations between the two groups, which suggests that lung cancer in patients who previously had breast cancer may not be affected at the genomic level by the previous breast cancer. The most important finding of the study was that a high percentage of women with lung cancer, regardless of breast-cancer history, did not meet the current USPSTF criteria for lung-cancer screening.
format Online
Article
Text
id pubmed-8765335
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-87653352022-01-19 Primary lung cancer in women after previous breast cancer Nobel, Tamar B Carr, Rebecca A Caso, Raul Livschitz, Jennifer Nussenzweig, Samuel Hsu, Meier Tan, Kay See Sihag, Smita Adusumilli, Prasad S Bott, Matthew J Downey, Robert J Huang, James Isbell, James M Park, Bernard J Rocco, Gaetano Rusch, Valerie W Jones, David R Molena, Daniela BJS Open Original Article BACKGROUND: Breast cancer is the most common malignancy among women in the USA. Improved survival has resulted in increasing incidence of second primary malignancies, of which lung cancer is the most common. The United States Preventive Services Task Force (USPSTF) guidelines for lung-cancer screening do not include previous malignancy as a high-risk feature requiring evaluation. The aim of this study was to compare women undergoing resection for lung cancer with and without a history of breast cancer and to assess whether there were differences in stage at diagnosis, survival and eligibility for lung-cancer screening between the two groups. METHODS: Women who underwent lung-cancer resection between 2000 and 2017 were identified. Demographic, clinicopathological, treatment and outcomes data were compared between patients with a history of breast cancer (BC-Lung) and patients without a history of breast cancer (P-Lung) before lung cancer. RESULTS: Of 2192 patients included, 331 (15.1 per cent) were in the BC-Lung group. The most common method of lung-cancer diagnosis in the BC-Lung group was breast-cancer surveillance or work-up imaging. Patients in the BC-Lung group had an earlier stage of lung cancer at the time of diagnosis. Five-year overall survival was not statistically significantly different between groups (73.3 per cent for both). Overall, 58.4 per cent of patients (1281 patients) had a history of smoking, and 33.3 per cent (731 patients) met the current criteria for lung-cancer screening. CONCLUSION: Differences in stage at diagnosis of lung cancer and treatment selection were observed between patients with and without a history of breast cancer. Overall, there were no statistically significant differences in genomic or oncogenic pathway alterations between the two groups, which suggests that lung cancer in patients who previously had breast cancer may not be affected at the genomic level by the previous breast cancer. The most important finding of the study was that a high percentage of women with lung cancer, regardless of breast-cancer history, did not meet the current USPSTF criteria for lung-cancer screening. Oxford University Press 2022-01-18 /pmc/articles/PMC8765335/ /pubmed/35040941 http://dx.doi.org/10.1093/bjsopen/zrab115 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Nobel, Tamar B
Carr, Rebecca A
Caso, Raul
Livschitz, Jennifer
Nussenzweig, Samuel
Hsu, Meier
Tan, Kay See
Sihag, Smita
Adusumilli, Prasad S
Bott, Matthew J
Downey, Robert J
Huang, James
Isbell, James M
Park, Bernard J
Rocco, Gaetano
Rusch, Valerie W
Jones, David R
Molena, Daniela
Primary lung cancer in women after previous breast cancer
title Primary lung cancer in women after previous breast cancer
title_full Primary lung cancer in women after previous breast cancer
title_fullStr Primary lung cancer in women after previous breast cancer
title_full_unstemmed Primary lung cancer in women after previous breast cancer
title_short Primary lung cancer in women after previous breast cancer
title_sort primary lung cancer in women after previous breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765335/
https://www.ncbi.nlm.nih.gov/pubmed/35040941
http://dx.doi.org/10.1093/bjsopen/zrab115
work_keys_str_mv AT nobeltamarb primarylungcancerinwomenafterpreviousbreastcancer
AT carrrebeccaa primarylungcancerinwomenafterpreviousbreastcancer
AT casoraul primarylungcancerinwomenafterpreviousbreastcancer
AT livschitzjennifer primarylungcancerinwomenafterpreviousbreastcancer
AT nussenzweigsamuel primarylungcancerinwomenafterpreviousbreastcancer
AT hsumeier primarylungcancerinwomenafterpreviousbreastcancer
AT tankaysee primarylungcancerinwomenafterpreviousbreastcancer
AT sihagsmita primarylungcancerinwomenafterpreviousbreastcancer
AT adusumilliprasads primarylungcancerinwomenafterpreviousbreastcancer
AT bottmatthewj primarylungcancerinwomenafterpreviousbreastcancer
AT downeyrobertj primarylungcancerinwomenafterpreviousbreastcancer
AT huangjames primarylungcancerinwomenafterpreviousbreastcancer
AT isbelljamesm primarylungcancerinwomenafterpreviousbreastcancer
AT parkbernardj primarylungcancerinwomenafterpreviousbreastcancer
AT roccogaetano primarylungcancerinwomenafterpreviousbreastcancer
AT ruschvaleriew primarylungcancerinwomenafterpreviousbreastcancer
AT jonesdavidr primarylungcancerinwomenafterpreviousbreastcancer
AT molenadaniela primarylungcancerinwomenafterpreviousbreastcancer